PTC Therapeutics, Inc.
HealthcareNASDAQ:PTCT · NASDAQ Global Select
+$0.42 today
Vol 1.07M · Avg 1.22M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$827.1M of revenue converted into -$186.7M of net income for the selected period. Gross margin is 78.6% and net margin is -27.9%, showing how much revenue survives after costs and taxes. EPS is $-2.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B +114.5% | $806.8M -14.0% | $937.8M +34.2% | $698.8M +29.7% | $538.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $71.8M +25.0% | $57.4M -12.4% | $65.5M +46.6% | $44.7M +38.2% | $32.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.7B +121.4% | $749.4M -14.1% | $872.3M +33.4% | $654.1M +29.2% | $506.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 95.9% +3.0pp | 92.9% -0.1pp | 93.0% -0.6pp | 93.6% -0.4pp | 94.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $455.2M -14.8% | $534.5M -19.8% | $666.6M +2.3% | $651.5M +20.5% | $540.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $347.1M +15.4% | $300.9M -9.5% | $332.5M +2.0% | $326.0M +14.1% | $285.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $802.4M -23.7% | $1.1B -19.8% | $1.3B +19.1% | $1.1B +25.1% | $880.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $38.8M -48.7% | $75.7M -68.0% | $236.6M +83.6% | $128.8M +100.9% | $64.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | $887.7M +836.9% | -$120.5M +63.5% | -$330.3M +10.2% | -$367.8M +0.1% | -$368.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 51.3% +66.2pp | -14.9% +20.3pp | -35.2% +17.4pp | -52.6% +15.7pp | -68.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $856.5M +383.1% | -$302.6M +31.2% | -$439.5M +1.8% | -$447.4M -19.5% | -$374.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 49.5% +87.0pp | -37.5% +9.4pp | -46.9% +17.2pp | -64.0% +5.5pp | -69.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $152.2M -8.8% | $167.0M +29.3% | $129.2M +42.2% | $90.9M +5.6% | $86.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$159.9M -164.1% | -$60.5M +76.4% | -$256.6M -83.2% | -$140.1M +2.7% | -$143.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $696.6M +291.8% | -$363.1M +47.8% | -$696.1M -18.5% | -$587.5M -13.3% | -$518.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 40.3% +85.3pp | -45.0% +29.2pp | -74.2% +9.8pp | -84.1% +12.2pp | -96.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $14.0M +7840.3% | $176.0K +100.3% | -$69.5M -144.1% | -$28.5M -612.0% | $5.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | $682.6M +287.9% | -$363.3M +42.0% | -$626.6M -12.1% | -$559.0M -6.7% | -$523.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 39.4% +84.5pp | -45.0% +21.8pp | -66.8% +13.2pp | -80.0% +17.3pp | -97.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $9 +281.4% | -$5 +43.5% | -$8 -7.4% | -$8 -4.8% | -$7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $8 +264.5% | -$5 +43.5% | -$8 -7.4% | -$8 -4.8% | -$7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $79.5M +3.5% | $76.8M +2.7% | $74.8M +4.3% | $71.7M +1.8% | $70.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $88.3M +14.9% | $76.8M +2.7% | $74.8M +4.3% | $71.7M +1.8% | $70.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.46B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.39B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.43B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.10B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
Arcellx, Inc.
ACLX
$6.73B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.67B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.06M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PTCT generate?
PTC Therapeutics, Inc. (PTCT) reported $1.73B of revenue in fiscal 2025.
Is PTCT profitable?
PTC Therapeutics, Inc. (PTCT) reported $682.64M of net income, with a net margin of 39.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.